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Patient iPSCs have potential as a
renewable source for autologous cell
therapy that avoids immune rejection.
Using a humanized mouse model with a
functional human immune system, Zhao
et al. observe differential immune
responses to various autologous hiPSC
derivatives, including rejection of smooth
muscle cells and tolerance to retinal
pigmented epithelium.
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The breakthrough of induced pluripotent stem cell
(iPSC) technology has raised the possibility that pa-
tient-specific iPSCsmay become a renewable source
of autologous cells for cell therapy without the con-
cern of immune rejection. However, the immunoge-
nicity of autologoushuman iPSC (hiPSC)-derivedcells
is not well understood. Using a humanized mouse
model (denoted Hu-mice) reconstituted with a func-
tional human immune system, we demonstrate that
most teratomas formed by autologous integration-
freehiPSCsexhibit local infiltrationof antigen-specific
T cells and associated tissue necrosis, indicating im-
mune rejection of certain hiPSC-derived cells. In this
context, autologous hiPSC-derived smooth muscle
cells (SMCs) appear to be highly immunogenic, while
autologous hiPSC-derived retinal pigment epithelial
(RPE) cells are immune tolerated even in non-ocular
locations. This differential immunogenicity is due in
part toabnormal expressionof immunogenicantigens
in hiPSC-derived SMCs, but not in hiPSC-derived
RPEs. These findings support the feasibility of devel-
oping hiPSC-derived RPEs for treating macular
degeneration.
INTRODUCTION
The recent breakthrough in the generation of induced pluripotent
stem cells (iPSCs) by reprogramming somatic cells with defined
factors has raised the hope that iPSCs, which are identical to
human embryonic stem cells (hESCs) in the context of pluripo-
tency, could become a renewable source of autologous cellsCell Sfor transplantation into human patients (Lewitzky and Yama-
naka, 2007). In addition, the disease-specific iPSCs could pro-
vide the unique opportunity to develop themuch needed disease
models in drug discovery. While it has been assumed that
the immune rejection problem challenging hESCs could be miti-
gated by the development of patient-specific hiPSCs without the
concern of immune rejection (Park et al., 2008; Takahashi et al.,
2007; Yu et al., 2007), recent studies have shown that certain cell
types derived from mouse iPSCs such as cardiomyocytes are
immunogenic in syngeneic recipients, and other immunogenic
cell types such as endothelial cells are immune tolerated by ex-
pressing high levels of immune-suppressive cytokines such as
IL-10 (Araki et al., 2013; de Almeida et al., 2014; Zhao et al.,
2011). Therefore, as an integral part of the effort to develop
hiPSCs into human cell therapy, it is important to evaluate the
immunogenicity of hiPSC-derived cells in the context of an autol-
ogous human immune system. To address this bottleneck, we
established humanized mouse models that are efficiently recon-
stituted with both T and B cells as well as macrophages and
dendritic cells required for antigen presentation (Figure S1A).
As we recently published (Rong et al., 2014), these Hu-mice
can mount vigorous immune rejection of allogeneic cells derived
from hESCs (Figures S1B–S1E). Therefore, the Hu-mice provide
a unique opportunity to examine the immunogenicity of autolo-
gous cells derived from hiPSCs.RESULTS
Teratomas Formed by hiPSCs Are Immunogenic to
Autologous Human T Cells
To generate autologous integration-free hiPSCs, fibroblasts
were derived from the same human fetal liver used to reconsti-
tute the human immune system in Hu-mice (Figure 1A). These
cells were reprogrammed into integration-free hiPSCswith either





Figure 1. Cells within Teratomas Formed by hiPSCs Can Be Immunogenic in Hu-Mice Reconstituted with Autologous Immune System
(A) Strategy to study the immunogenicity of hiPSC derivatives. Human fetal liver/thymus and autologous CD34+ fetal liver cells were transplanted into NSGmice to
generate Hu-mice. Fibroblasts were isolated from the same fetal liver and reprogrammed into autologous integration-free hiPSCs, which were either directly
transplanted into the Hu-mice or differentiated into mature cell types before being transplanted into Hu-mice.
(B) T cell infiltration was detected in the majority of teratomas formed by hiPSCs in Hu-mice with autologous human immune system. T cells are revealed by their
dark brown color.
(C) The summary of teratoma formation and T cell infiltration into teratomas after subcutaneous implantation of nine independent hiPSC lines reprogrammed from
five different donors as well as Zg16-hiPSCs in Hu-mice reconstituted with corresponding autologous immune system.
(D) Low magnification (43) images show the apparent difference in T cell infiltration between hESC-derived teratoma and autologous iPSC-derived teratoma.
(E) Frequency of T cells infiltrating each teratoma. Sections of teratomas formed by Hues8, Hues9, chiPS1a, and chiPS2a in Hu-mice were stained with anti-CD3
antibody. Five teratomas from each line were analyzed. At least 50 frames (203) from each teratoma were randomly chosen for analysis. The numbers of T cells
detected were categorized into three groups: 0–3, 4–19, orR20 T cells per frame.2011) or those developed by the Yamanaka group (Okita et al.,
2011). The hiPSCs are positive for alkaline phosphatase, express
pluripotency markers to the same levels as hESCs, have normal
karyotypes, and can form teratomas containing cells derived
from each of the three germ layers in immunodeficient mice,
confirming their pluripotency (Figures S2A–S2D). In addition,
Southern blotting analysis with probes covering the entire
episomal vector further confirmed that hiPSCs are integration
free (Figure S2E). These integration-free hiPSCs were trans-
planted subcutaneously into Hu-mice to form teratomas, allow-
ing the simultaneous evaluation of the immunogenicity of various
cell types differentiated from hiPSCs.
Serial section analysis of the teratomas formed by hiPSCs in
Hu-mice reconstitutedwith autologous immune system indicated
that the majority of these teratomas contained regions that were
infiltrated with human CD4+ and CD8+ T cells and exhibited
tissue necrosis (Figures 1B and 1C; Figure S1K). However,
the immunogenicity of autologous hiPSC-derived teratomas in
Hu-mice appeared to be much weaker than allogeneic hESC-
derived teratomas that were extensively infiltrated with T cells354 Cell Stem Cell 17, 353–359, September 3, 2015 ª2015 Elsevier I(Figures 1D and 1E). In this context, after examining sequential
sections of one teratoma formed by autologous hiPSCs in Hu-
mice, we did not detect any T cell infiltration (Figure S1L). There-
fore, certain, but not all, cells derived from hiPSCs are immuno-
genic to the autologous human immune system.
T Cell Response to Specific Cell Types within
Autologous Teratomas
To identify the potential immunogenic tissues inside the tera-
toma, we analyzed the histology of a large number of teratomas
infiltrated with T cells. We found that the autologous hiPSC-
derived Desmin+ smooth muscle cells (SMCs) were frequently
surrounded by infiltrating T cells in the teratomas (Figures 2A
and 2C). In contrast, the majority of autologous hiPSC-derived
retinal pigment epithelium (RPE) cells within the teratomas
were not surrounded by T cells (Figures 2B and 2C).
To further characterize the T cell responses to the teratomas
formed by autologous hiPSCs, we performed deep sequencing
to analyze the T cell receptor (TCR) repertoire of the T cells
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Figure 2. Characterization of the Immune Responses to the Teratomas Formed by hiPSCs in Hu-Mice Reconstituted with Autologous
Immune System
(A) Smooth muscle cells (SMCs) within the teratomas formed by hiPSCs in Hu-mice are frequently infiltrated with T cells (green arrow: smooth muscle cells; blue
arrow: T cells).
(B) The retinal pigment epithelium (RPE) cells within the teratomas formed by hiPSCs are immune tolerated.
(C) Summary of the T cell infiltration into SMCs and RPEs within the teratomas formed by hiPSCs in Hu-mice reconstituted with autologous immune system.
(D) TCR repertoire distributions in four teratomas formed by Hues9 and two independent hiPSC lines (chiPS-2a and chiPS-2b) in Hu-mice. 2D: two-dimensional
map; dot: different TCR, with the change of color from blue to red representing the enrichment of the specific TCR; 3D: three-dimensionL map; blue column:
enrichment of the specific TCR. The enrichment of several monoclonal TCRS in hiPSC-derived teratomas suggests the antigen-specific T cell response to cells
within the teratomas formed by autologous iPSCs.hESCs or autologous hiPSCs (Figure 2D). Intriguingly, in contrast
to the highly polyclonal nature of the TCR repertoire of T cells
infiltrated into the allogeneic hESC-derived teratomas, the TCR
repertoire of T cells infiltrating into the teratomas formed by
autologous hiPSCs in Hu-mice was oligoclonal, indicating anti-
gen-specific T cell responses to the autologous hiPSC-derived
cells within the teratomas.
Differential Immunogenicity of SMCs and RPEs Derived
from Autologous hiPSCs
To further evaluate the immunogenicity of hiPSC-derived RPE
cells, we differentiated the autologous hiPSCs into RPE cells
in vitro with a high efficiency protocol as previously described
(Krohne et al., 2012). As a positive control, allogeneic hESCs
were also differentiated into RPE cells. hiPSC-derived RPEs
were tightly coupled, positive for Mitf and Bestrophin, exhibited
vectorial transport of water and ions, phagocytosed photo-
receptor outer segments (POSs), could be incorporated into
diseased retinas in a polarized monolayer, and rescued photore-
ceptors in an animal model (RCS rats) of RPE-mediated retinal
degeneration (Figures S3A–S3G). Furthermore, the global gene
expression analysis demonstrated a high similarity between
hiPSC-derived RPEs and the human primary RPEs (Figures 4A
and 4B). These findings validated the identity and function of
hiPSC-derived RPEs. The autologous hiPSC-derived RPEs andCell Sthe control allogeneic hESC-derived RPEs were transplanted
into the eye of Hu-mice. Since the eye is considered an im-
mune-privileged site, and thus, could mask the immunogenicity
of the hiPSC-derived RPE cells, we also implanted these RPEs
into the hindleg skeletal muscle of Hu-mice. In support of this
concept, even the allogeneic hESC-derived RPE cells survived
in the eye of Hu-mice without apparent immune rejection.
When injected into the skeletal muscle of Hu-mice, the alloge-
neic hESC-derived RPEs were infiltrated with T cells, consistent
with T-dependent immune rejection (Figures 3A, 3C, 3D, and
3G). In contrast, autologous hiPSC-derived RPEs implanted in
the muscle of the same Hu-mice were mostly protected from
T cells (Figures 3B–3D and 3G). Therefore, we conclude that
hiPSC-derived RPEs have low immunogenicity.
The studies of teratomas formed by hiPSCs in Hu-mice sug-
gest that SMCs derived from hiPSCs might be immunogenic to
the autologous immune system. To further investigate the immu-
nogenicity of SMCs differentiated from autologous hiPSCs, we
efficiently derived SMCs from hiPSCs using established pro-
tocols (Huang et al., 2006). The hiPSC-derived SMCs expressed
SMC-specific markers and were associated with vascular
networks in vitro and in vivo, validating their functionality as
SMCs (Figures S4H–S4K). In addition, the profile of the global
gene expression showed high similarity between hiPSC-derived






Figure 3. The Immunogenicity of RPE Cells and SMCs Differentiated from hiPSCs in Hu-Mice Reconstituted with Autologous Immune
System
(A) The RPEs differentiated from H9 hESCs were infiltrated with T cells 5 weeks after being transplanted into the hindleg muscle of the Hu-mice. Blue arrow
indicates the infiltrated T cells. H&E staining of H9-derived RPE cells transplanted into the hindleg muscle of the Hu-mice is shown. Otx2 staining shows the well-
differentiated RPE cells (green: Otx2; blue: DAPI) transplanted into the hindleg muscle of Hu-mice.
(B) The hiPSC-derived RPEs are not infiltrated with T cells 5 weeks after being transplanted into the hindleg muscle of the Hu-mice reconstituted with autologous
immune system. H&E staining of hiPSC-derived RPEs transplanted into the hindleg muscle of Hu-mice is shown. Otx2 staining shows hiPSC-derived RPEs; red:
mouse muscle.
(C) The co-staining of anti-Otx2 and anti-CD4 antibodies confirmed the status of T cell infiltration into the allogenic hESC-derived and autologous hiPSC-derived
RPEs transplanted into the Hu-mice. Green: Otx2; red: CD4; blue: DAPI.
(D) Summary of T cell infiltration into RPE cells differentiated from four independent hiPSCs reprogrammed from three donors after being transplanted into Hu-
mice reconstituted with autologous human immune system.
(E) SMCs differentiated from hiPSCs in vitro were immunogenic in Hu-mice reconstituted with autologous immune system. hiPSC-derived SMCs were trans-
planted into hindleg muscle of Hu-mice reconstituted with autologous human immune system. Five weeks later, the transplants were harvested and stained with
indicated antibodies, showing infiltration of T cells into the SMC grafts. SM22 and SMA, smooth muscle markers; HuNu, human nuclei. Cell nuclei were
counterstained with DAPI.
(F) Summary of T cell infiltration into SMCs differentiated from two independent hiPSCs reprogrammed from two donors after being transplanted into Hu-mice
reconstituted with autologous human immune system.
(G) Frequency of T cell infiltration into the grafts of hiPSC-RPEs and hiPSC-SMCs in Hu-mice with autologous immune system. Sections of grafts were stained
with anti-CD3 antibody. Three sections from each graft were analyzed. At least 10 frames (203) from each slide were randomly chosen for analysis. The numbers
of T cells detected were categorized into three groups: 0–3, 4–9, orR10 T cells per frame.
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Figure 4. Abnormal Expression of Immunogenic Antigens Contributes to the Differential Immunogenicity of hiPSC-Derived SMCs and RPEs
(A) The global gene expression was profiled by oligonucleotide DNA microarrays and compared between hiPSCs and hiPSC-derived SMCs (hiPSC-SMCs),
human primary SMCs and hiPSC-SMCs, hiPSCs and hiPSC-derived RPEs (hiPSC-RPEs), human primary RPEs and hiPSC-RPEs. The blue lines indicate the
diagonal and 3-fold changes between the two samples.
(B–D) The gene expression similarity between various samples (B). The overexpression of the Zg16 gene in hiPSC-SMCs (C) and RPEs differentiated from Zg16-
hiPSCs (D) was confirmed by qPCR.
(E) The RPE cells derived from Zg16-hiPSCs are immunogenic in Hu-mice with autologous immune system. The Zg16-RPE grafts were extensively infiltrated by
T cells and mostly rejected 2 weeks after being transplantated into the hindleg muscle of Hu-mice with autologous immune system. As a control, the same batch
of Zg16-RPEs were injected into the hindleg muscle of NSG mice, and they survived 3 weeks after transplantation.
(F) Frequency of T cell infiltration into the grafts of RPEs derived from Zg16-hiPSCs in Hu-mice as quantified in Figure 2G.of hiPSC-derived SMCs. The hiPSC-derived SMCs were trans-
planted into the skeletal muscle of Hu-mice reconstituted with
autologous human immune system. When analyzed by serial
sections, the hiPSC-derived SMC grafts were uniformly infil-
trated with T cells, confirming that hiPSC-derived SMCs are
immunogenic to autologous human immune system (Figures
3E–3G).
Misexpression of Immunogenic Antigens Induces T Cell
Responses to hiPSC-Derived SMCs
The overexpression of IL-10 has been shown to induce immune
tolerance of mouse iPSC-derived endothelial cells in syngeneic
recipients (de Almeida et al., 2014). However, the immune toler-
ance of hiPSC-derived RPEs is not due to the lack of HLA
expression or the overexpression of immune-suppressive cyto-
kines such as IL-10 (Figure S3). To understand the mechanism
underlying the differential immunogenicity of hiPSC-derived
RPEs and SMCs, we screened these cells for the expression ofCell Spotential immunogenic antigens. While the global gene expres-
sion of hiPSC-derived SMCs and RPEs exhibited close to 90%
similarity to their primary counterparts, we found that the expres-
sion of Zg16, an immunogenic antigen, was greatly increased
in hiPSC-derived SMCs, but not in hiPSC-derived RPEs (Fig-
ure 4C). In addition, another immunogenic antigen, Hormad1,
was also overexpressed in the hiPSC-derived SMCs (Fig-
ure S4G). To determine whether the abnormal expression of
immunogenic antigens induces the immunogenicity of hiPSC-
derived cells, we ectopically expressed Zg16 in iPSCs (Zg16-
hiPSCs). This blocked the teratoma formation of Zg16-hiPSCs
in Hu-mice with autologous immune system, suggesting that
Zg16-hiPSCs are immune rejected (Figure 1C). More impor-
tantly, in contrast to hiPSC-RPEs that are immune protected
from autologous immune system, RPEs differentiated from
Zg16-hiPSCs expressed Zg16 and were immune rejected by
autologous immune system (Figures 4D and 4E). Together
with previous findings that the abnormal expression of thesetem Cell 17, 353–359, September 3, 2015 ª2015 Elsevier Inc. 357
immunogenic antigens (Zg16 and Hormad1) can directly induce
antigen-specific T cell responses to mouse iPSC-derived cells
transplanted in syngeneic mice (Zhao et al., 2011), these data
support the notion that the abnormal expression of immunogenic
antigens in hiPSC-derived SMCs induces their immunogenicity
to autologous human immune system.DISCUSSION
Using inbred mouse strains, recent studies have revealed the
immunogenicity of the cells derived from mouse iPSCs (Araki
et al., 2013; de Almeida et al., 2014; Zhao et al., 2011). While
the debate on the levels of immunogenicity of cells derived
from mouse iPSCs in syngeneic recipients is ongoing, these
mouse studies support the notion that certain cells such as car-
diomyocytes derived from mouse iPSCs in vitro are immuno-
genic in syngeneic recipients (Araki et al., 2013; de Almeida
et al., 2014; Guha et al., 2013; Zhao et al., 2011). Therefore, to
achieve the potential of hiPSCs in human cell therapy, it is impor-
tant to evaluate the immunogenicity of the cells differentiated
from hiPSCs. We demonstrated that certain hiPSC-derived cells
such as RPE cells aremuch less immunogenic than other hiPSC-
derived cell types such as SMCs. The mechanisms underlying
the differential immunogenicity can be very complex, depending
on the intrinsic immune characteristics of the cell types and the
impact of epigenetic abnormality of hiPSCs on differentiated
cell types as previously noted (Bar-Nur et al., 2011; Bock et al.,
2011; Kim et al., 2010, 2011; Polo et al., 2010; Ruiz et al.,
2012). In support of this notion, we demonstrate that the
abnormal expression of immunogenic antigens in some hiPSC-
derived cells, but not in others, contributes to the differential
immunogenicity. Consistent with this finding, immunogenic anti-
gens are also overexpressed during the differentiation of mouse
iPSCs, but not during the differentiation of mouse ESCs, leading
to antigen-specific T cell responses to iPSC-derived cells in syn-
geneic recipients (Araki et al., 2013; de Almeida et al., 2014; Zhao
et al., 2011). While SMCs differentiated from hiPSCs exhibit
functionalities and global gene expression profiles highly similar
to those of normal human counterparts, the finding that the
immunogenic antigens expressed in hiPSC-derived SMCs are
not expressed by normal human SMCs suggests that further
improvement of the robustness of the differentiation process of
hiPSCs could help to reduce the immunogenicity of hiPSC-
derived cells. Finally, our findings of the lack of immunogenicity
of hiPSC-derived RPEs support the feasibility of developing
hiPSC-derived RPE cells for treating atrophic age-related macu-
lar degeneration.EXPERIMENTAL PROCEDURES
Reconstitution of Humanized Mice
The NOD/SCID/g null (NSG) mice were purchased from the Jackson Labora-
tories at 7–10 weeks of age. Human fetal thymus and liver tissues at age 17–
20 weeks were obtained from Advanced Bioscience Resource. All protocols
used for human tissues and animal manipulation have been approved by Uni-
versity of California San Diego Research Committees on human subjects and
research animal care.
Hu-mice were generated as previously described (Lan et al., 2006). Briefly,
the NSG mice were first treated with sublethal irradiation (2 Gy), and human
fetal thymus and liver pieces (1 mm3) were transplanted under the kidney358 Cell Stem Cell 17, 353–359, September 3, 2015 ª2015 Elsevier Icapsule of the irradiated NSG mice. The human CD34+ cells were simulta-
neously purified from the same human fetal liver using aMACS separation sys-
temwith anti-human CD34+ antibody (Miltenyi Biotec), and 1 to 53 105 human
CD34+ cells were intravenously transfused into the same mice.
Generation of Integration-free hiPSCs
The fibroblasts derived from human fetal liver were reprogrammed into hiPSCs
with episomal approaches as previously described (Okita et al., 2011; Zhao
et al., 2011) After puromycin selection, the transfected cells were plated on
feeder layer, and the hiPSC colonies were mechanically picked, dissected
into small pieces, and plated onto the feeder layer in a 24-well plate. Southern
blotting analysis or real-time PCR was used to confirm that the hiPSCs were
integration-free as described.
Histological Analysis
Tissues were harvested and frozen in OCT (for immunohistochemical and fluo-
rescent staining) or fixed in 10% buffered formalin and embedded in paraffin
(for H7&E staining). Antibodies include polyclonal rabbit anti-human CD3 anti-
body (DAKO), mouse anti–human CD4mAb (RPA-T4, BD PharMingen), mouse
anti-human CD8 mAb (RPA-T8, BD PharMingen), and mouse anti-human
CD123 mAb (6H6; eBioscience).
TCR Repertoire Analysis of Infiltrating T Cells
Total RNA was extracted from explanted grafts using QIAGEN RNA extraction
kits (QIAGEN). TCRb repertoires were amplified and sequenced using Illumina
MiSeq by iRepertoire Inc. (Huntsville). Data analysis was performed using the
website provided by iRepertoire Inc. (http://www.irepertoire.com).
Differentiation of hiPSC/hESCs into RPEs and SMCs In Vitro
The differentiation of hiPSCs/hESCs into RPEs and subsequent expansion
were performed as previously described (Krohne et al., 2012). Briefly,
hiPSCs/hESCs were maintained in serum-free differentiation media consisting
of Knockout DMEM (Invitrogen), 2mM glutamine (Invitrogen), 0.1mM NEAA
(Invitrogen), 0.1mM b-mercaptoethanol (Sigma-Aldrich), 100 U/ml penicillin
(Invitrogen), 100 mg/ml streptomycin (Invitrogen), and 20% Knockout Serum
Replacement (Invitrogen). Pigmented colonies began appearing after about
6 weeks. Once they reached adequate size, the colonies were manually
excised and placed onto plates coated with Matrigel (Becton Dickinson).
Only very low-passage cells (P1–P3) were used in these experiments.
To enable expression of Zg16 in the hiPSC-derived RPEs, the human
Zg16 cDNA was inserted downstream of the CAG promoter of an episomal
vector we used for iPSC reprogramming (Zhao et al., 2011) and electropo-
rated into hiPSC lines. The empty vector was used as a control. The hiPSC
lines with stable Zg16 expression were differentiated into Zg16-expressing
RPEs.
Subretinal Injections
Subretinal injections were performed as described previously (Krohne et al.,
2012). Briefly, the eyes from deeply anaesthetized mice were pierced with a
sharp 30G needle (Becton Dickinson) just below the limbus. A blunt-tipped
33G Hamilton syringe (Hamilton) was used to deliver roughly 100,000 cells in
suspension into the subretinal space using a transscleral route through the dia-
metrically opposed retina.
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